Tyligand Bioscience

Shanghai, China · Founded 2018 · In IPO Registration

Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.

Last reported valuation

$222.2M

Oct 2026

Priced at

—

Total raised

$110.6M

Last round

—

How much has Tyligand Bioscience raised?

$110.6Macross 0 recorded rounds

Free account

More of Tyligand Bioscience with a free account

·The complete investor list: 14 names
·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Tyligand Bioscience investors

14 investors are on record for Tyligand Bioscience, including Suzhou Oriza Holdings Corporation, K2VC, Tailong VC and Suzhou Yuanfeng Capital Management.

For fundraisers

Raising for a company like Tyligand Bioscience?

14 investors have backed Tyligand Bioscience.

See all 14 investors →

Frequently asked about Tyligand Bioscience

How much has Tyligand Bioscience raised?: Tyligand Bioscience has raised $110.6M in total across 0 recorded funding rounds.